Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasm Recurrence, Local | 14 | 2020 | 9433 | 0.450 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11854 | 0.420 |
Why?
|
HIV-1 | 10 | 2023 | 6963 | 0.370 |
Why?
|
Androgen Antagonists | 5 | 2018 | 1421 | 0.320 |
Why?
|
Models, Statistical | 3 | 2008 | 5099 | 0.310 |
Why?
|
Carcinoma, Renal Cell | 6 | 2019 | 3199 | 0.290 |
Why?
|
HIV Seropositivity | 2 | 2023 | 962 | 0.270 |
Why?
|
Prostatic Neoplasms | 10 | 2018 | 11220 | 0.260 |
Why?
|
Patient Dropouts | 1 | 2008 | 411 | 0.260 |
Why?
|
Aromatase | 2 | 2016 | 147 | 0.250 |
Why?
|
Disease-Free Survival | 7 | 2024 | 6856 | 0.250 |
Why?
|
Breast Neoplasms | 11 | 2020 | 21163 | 0.230 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 1105 | 0.230 |
Why?
|
Nitriles | 4 | 2020 | 984 | 0.220 |
Why?
|
HIV Infections | 12 | 2023 | 17575 | 0.220 |
Why?
|
Survival Analysis | 7 | 2019 | 10117 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2020 | 567 | 0.210 |
Why?
|
PTEN Phosphohydrolase | 2 | 2018 | 1118 | 0.210 |
Why?
|
Receptors, Estrogen | 4 | 2020 | 2247 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 12 | 2020 | 6541 | 0.200 |
Why?
|
Receptors, Androgen | 2 | 2020 | 1083 | 0.200 |
Why?
|
Estrogen Receptor alpha | 2 | 2016 | 580 | 0.200 |
Why?
|
Cytidine Deaminase | 2 | 2014 | 243 | 0.190 |
Why?
|
Ritonavir | 2 | 2008 | 330 | 0.190 |
Why?
|
Tamoxifen | 3 | 2016 | 968 | 0.190 |
Why?
|
Lead Poisoning | 1 | 2023 | 323 | 0.180 |
Why?
|
Viral Load | 6 | 2008 | 3398 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2018 | 1536 | 0.170 |
Why?
|
Central Nervous System Diseases | 3 | 2013 | 523 | 0.170 |
Why?
|
HIV Integrase Inhibitors | 1 | 2022 | 165 | 0.170 |
Why?
|
Anti-HIV Agents | 4 | 2023 | 4571 | 0.160 |
Why?
|
Triazoles | 2 | 2015 | 904 | 0.160 |
Why?
|
Neoplasm Metastasis | 6 | 2019 | 4921 | 0.150 |
Why?
|
HIV Protease Inhibitors | 3 | 2008 | 432 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 102 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 10377 | 0.150 |
Why?
|
RNA, Viral | 6 | 2023 | 2866 | 0.150 |
Why?
|
Cyclophosphamide | 3 | 2024 | 2226 | 0.150 |
Why?
|
Testicular Neoplasms | 2 | 2014 | 805 | 0.150 |
Why?
|
Lead | 1 | 2023 | 880 | 0.150 |
Why?
|
Radium | 1 | 2018 | 72 | 0.150 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2007 | 1903 | 0.150 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4301 | 0.140 |
Why?
|
Mannose-Binding Lectin | 1 | 2008 | 146 | 0.140 |
Why?
|
Methotrexate | 3 | 2024 | 1722 | 0.140 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2017 | 121 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 356 | 0.140 |
Why?
|
Bone Diseases | 1 | 2020 | 417 | 0.140 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2004 | 622 | 0.130 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2016 | 23 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 433 | 0.130 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 2708 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 424 | 0.130 |
Why?
|
Postmenopause | 3 | 2020 | 2518 | 0.130 |
Why?
|
Taxoids | 2 | 2019 | 668 | 0.130 |
Why?
|
Colonic Polyps | 1 | 2020 | 557 | 0.130 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2019 | 480 | 0.120 |
Why?
|
Ovary | 2 | 2018 | 960 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2018 | 3553 | 0.120 |
Why?
|
Estrogen Receptor beta | 1 | 2015 | 171 | 0.120 |
Why?
|
Mortality | 1 | 2006 | 2917 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2018 | 1145 | 0.110 |
Why?
|
Prognosis | 13 | 2024 | 30020 | 0.110 |
Why?
|
Prostatectomy | 2 | 2018 | 1841 | 0.110 |
Why?
|
Middle Aged | 35 | 2020 | 223463 | 0.110 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 126 | 0.110 |
Why?
|
Dideoxynucleosides | 1 | 2003 | 135 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 797 | 0.110 |
Why?
|
Seminoma | 1 | 2013 | 136 | 0.100 |
Why?
|
Orchiectomy | 2 | 2014 | 466 | 0.100 |
Why?
|
Colonoscopy | 1 | 2020 | 1412 | 0.100 |
Why?
|
Neoplasm Staging | 8 | 2019 | 11254 | 0.100 |
Why?
|
Tablets | 2 | 2023 | 149 | 0.100 |
Why?
|
Humans | 59 | 2024 | 768298 | 0.100 |
Why?
|
Aged | 27 | 2020 | 171544 | 0.100 |
Why?
|
Pyridones | 3 | 2023 | 818 | 0.100 |
Why?
|
Prostate-Specific Antigen | 6 | 2019 | 2487 | 0.100 |
Why?
|
Chemokine CCL2 | 1 | 2014 | 606 | 0.090 |
Why?
|
Female | 38 | 2024 | 397050 | 0.090 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2014 | 335 | 0.090 |
Why?
|
Interleukin-8 | 1 | 2014 | 704 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 876 | 0.090 |
Why?
|
Androgens | 2 | 2016 | 1285 | 0.090 |
Why?
|
Prostate | 1 | 2018 | 1780 | 0.090 |
Why?
|
Alleles | 4 | 2015 | 6892 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2019 | 1382 | 0.080 |
Why?
|
Adenoma | 1 | 2020 | 2163 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2020 | 16027 | 0.080 |
Why?
|
Survival Rate | 6 | 2020 | 12870 | 0.080 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 494 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1902 | 0.080 |
Why?
|
Male | 34 | 2024 | 364870 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 677 | 0.080 |
Why?
|
Estrogens | 1 | 2016 | 1534 | 0.080 |
Why?
|
Phenylthiohydantoin | 2 | 2020 | 208 | 0.080 |
Why?
|
Pyrones | 1 | 2008 | 35 | 0.080 |
Why?
|
Sarcoma | 1 | 2019 | 1806 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2950 | 0.070 |
Why?
|
Mutation | 5 | 2020 | 30230 | 0.070 |
Why?
|
Disease Progression | 6 | 2019 | 13646 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2015 | 6404 | 0.070 |
Why?
|
HIV | 1 | 2004 | 1596 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 1195 | 0.070 |
Why?
|
Adult | 21 | 2024 | 223622 | 0.070 |
Why?
|
Aged, 80 and over | 12 | 2020 | 59683 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3520 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2019 | 2044 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2066 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 4 | 2007 | 2596 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2020 | 65365 | 0.070 |
Why?
|
Doxorubicin | 1 | 2013 | 2229 | 0.070 |
Why?
|
Genotype | 6 | 2018 | 13038 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39405 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2565 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2811 | 0.060 |
Why?
|
HLA Antigens | 1 | 2011 | 1337 | 0.060 |
Why?
|
Tumor Burden | 3 | 2018 | 1913 | 0.060 |
Why?
|
Likelihood Functions | 1 | 2008 | 993 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2008 | 594 | 0.060 |
Why?
|
Infant | 7 | 2024 | 36512 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2202 | 0.060 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12557 | 0.060 |
Why?
|
Benzamides | 2 | 2020 | 1380 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5451 | 0.060 |
Why?
|
Didanosine | 1 | 2004 | 151 | 0.060 |
Why?
|
Forkhead Transcription Factors | 2 | 2024 | 1622 | 0.060 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 109 | 0.060 |
Why?
|
Time Factors | 8 | 2019 | 40267 | 0.060 |
Why?
|
Adolescent | 12 | 2023 | 89182 | 0.060 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 13696 | 0.060 |
Why?
|
Computer Simulation | 2 | 2008 | 6277 | 0.060 |
Why?
|
Child | 10 | 2024 | 80894 | 0.050 |
Why?
|
Child, Preschool | 7 | 2024 | 42654 | 0.050 |
Why?
|
Hot Flashes | 2 | 2016 | 330 | 0.050 |
Why?
|
Hydroxyurea | 1 | 2004 | 284 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2741 | 0.050 |
Why?
|
Indinavir | 1 | 2003 | 73 | 0.050 |
Why?
|
Rifabutin | 1 | 2003 | 59 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2862 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3471 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2019 | 4908 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.050 |
Why?
|
Retrospective Studies | 11 | 2023 | 81768 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9261 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 367 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6606 | 0.050 |
Why?
|
Risk Factors | 8 | 2020 | 74954 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6969 | 0.040 |
Why?
|
Poland | 1 | 2020 | 197 | 0.040 |
Why?
|
Austria | 1 | 2020 | 209 | 0.040 |
Why?
|
Piperazines | 2 | 2022 | 2552 | 0.040 |
Why?
|
Estradiol | 2 | 2018 | 1952 | 0.040 |
Why?
|
Oxazines | 1 | 2022 | 357 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4859 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2023 | 5311 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8562 | 0.040 |
Why?
|
Odds Ratio | 3 | 2018 | 9681 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2017 | 8628 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2022 | 295 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5707 | 0.040 |
Why?
|
Logistic Models | 3 | 2023 | 13323 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 60 | 0.040 |
Why?
|
Aging | 1 | 2008 | 8764 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 468 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2019 | 330 | 0.040 |
Why?
|
Drug Therapy, Combination | 4 | 2008 | 6319 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 252 | 0.040 |
Why?
|
Cohort Studies | 6 | 2019 | 41791 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14736 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3666 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 397 | 0.030 |
Why?
|
Young Adult | 6 | 2023 | 60048 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 551 | 0.030 |
Why?
|
Incidence | 2 | 2020 | 21544 | 0.030 |
Why?
|
Anthracyclines | 1 | 2019 | 286 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.030 |
Why?
|
Radioisotopes | 1 | 2018 | 517 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2019 | 386 | 0.030 |
Why?
|
Pyridines | 1 | 2008 | 2889 | 0.030 |
Why?
|
Morpholines | 1 | 2019 | 584 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 305 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2924 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2018 | 410 | 0.030 |
Why?
|
Medical Oncology | 1 | 2008 | 2348 | 0.030 |
Why?
|
Sweating | 1 | 2016 | 155 | 0.030 |
Why?
|
Aminopyridines | 1 | 2019 | 580 | 0.030 |
Why?
|
Risk Assessment | 4 | 2020 | 24316 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1760 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1876 | 0.030 |
Why?
|
Up-Regulation | 2 | 2014 | 4137 | 0.030 |
Why?
|
Estrone | 1 | 2016 | 234 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 13050 | 0.030 |
Why?
|
Software | 1 | 2008 | 4452 | 0.030 |
Why?
|
Premenopause | 1 | 2018 | 1039 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 583 | 0.030 |
Why?
|
Sulfonamides | 2 | 2018 | 1980 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1064 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2018 | 2474 | 0.030 |
Why?
|
Androstadienes | 1 | 2016 | 348 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2020 | 1780 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 2016 | 726 | 0.030 |
Why?
|
Family | 1 | 2024 | 3208 | 0.030 |
Why?
|
Oligopeptides | 1 | 2018 | 1194 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 2016 | 821 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2014 | 303 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1794 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2018 | 1149 | 0.030 |
Why?
|
Estrogen Receptor Modulators | 1 | 2012 | 58 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9508 | 0.030 |
Why?
|
Colon | 1 | 2020 | 1805 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.020 |
Why?
|
Registries | 2 | 2019 | 8378 | 0.020 |
Why?
|
Research Design | 1 | 2008 | 6209 | 0.020 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 3236 | 0.020 |
Why?
|
Haplotypes | 1 | 2008 | 2724 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2014 | 753 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20766 | 0.020 |
Why?
|
Parents | 1 | 2024 | 3596 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1748 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2461 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 13082 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 17132 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2016 | 1748 | 0.020 |
Why?
|
Signal Transduction | 3 | 2019 | 23629 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3064 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4120 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15455 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2016 | 684 | 0.020 |
Why?
|
Virus Replication | 1 | 2007 | 2458 | 0.020 |
Why?
|
Liposomes | 1 | 2013 | 792 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1658 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2986 | 0.020 |
Why?
|
Pyrazoles | 1 | 2019 | 2021 | 0.020 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 519 | 0.020 |
Why?
|
Risk-Taking | 1 | 2004 | 1026 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 18047 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1117 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2013 | 961 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 1226 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2013 | 1274 | 0.020 |
Why?
|
Nephrectomy | 1 | 2012 | 949 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 14154 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2909 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2018 | 22292 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2015 | 12457 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10776 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11117 | 0.020 |
Why?
|
United States | 3 | 2020 | 73144 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5792 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 3048 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2008 | 604 | 0.020 |
Why?
|
Leptin | 1 | 2013 | 1597 | 0.020 |
Why?
|
Computational Biology | 1 | 2017 | 3541 | 0.020 |
Why?
|
Blood Coagulation Disorders | 1 | 2008 | 350 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5511 | 0.020 |
Why?
|
Vomiting | 1 | 2008 | 655 | 0.020 |
Why?
|
Quality of Life | 2 | 2019 | 13499 | 0.010 |
Why?
|
Clinical Competence | 1 | 2020 | 4847 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 54921 | 0.010 |
Why?
|
Genomics | 1 | 2020 | 5916 | 0.010 |
Why?
|
Mastectomy | 1 | 2013 | 1851 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 6350 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7458 | 0.010 |
Why?
|
DNA, Viral | 1 | 2011 | 2205 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8750 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13576 | 0.010 |
Why?
|
Pain | 1 | 2018 | 5102 | 0.010 |
Why?
|
Models, Biological | 1 | 2018 | 9494 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14481 | 0.010 |
Why?
|
Recurrence | 1 | 2014 | 8501 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6084 | 0.010 |
Why?
|
Diarrhea | 1 | 2008 | 1320 | 0.010 |
Why?
|
Cognition | 1 | 2008 | 7074 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10464 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12092 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12801 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1642 | 0.010 |
Why?
|
Drug Interactions | 1 | 2003 | 1420 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10588 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12775 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2007 | 26410 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2003 | 2106 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20224 | 0.010 |
Why?
|
Mice | 1 | 2017 | 82004 | 0.010 |
Why?
|
Animals | 1 | 2017 | 169322 | 0.000 |
Why?
|